Castrellon, Pidhorecky, Valero, and Raez: The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer

Abstract

Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.




Introduction

Triple-negative breast cancer (TNBC) accounts for approximately 20 percent of breast cancers (BC) diagnosed worldwide, representing almost 200,000 cases each year.1 Epidemiologic studies illustrate a high prevalence of TNBC among younger women, when compared to the other BC subtypes. These patients are also at higher risk to develop brain or visceral metastasis.2-5 In addition, it appears to be more common among black woman than whites, and is associated with the BRCA1 genetic mutation.6,7 TNBC is characterized by the absence of expression of the estrogen (ER), progesterone receptors (PR) and lack of amplification of the human epidermal growth factor receptor 2 (HER2)/Neu gene.8 Unlike hormonal receptor positive (HR+) and HER2 overexpressing breast cancers, TNBC is unresponsive to endocrine therapy and HER2-targeted agents and treatment options are limited to conventional cytotoxic chemotherapy.9 Chemotherapy has been effective in the treatment of early-stage disease, with pathologic complete response (pCR) rates exceeding those of HR+ subtypes.10,11 Patients with metastatic disease however experience rapid progression through several lines of chemotherapy, and overall survival (OS) in the metastatic setting is usually poor with reports being between 9 and 13 months.12 Pathologic complete response rates to neoadjuvant chemotherapy (NACT) among patients with TNBC range from 27-45%, while pCR rate for patients with HER2 negative/HR+ breast cancer is generally around 10-20%.13,14 Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease free survival (DFS) and OS.14,15 However, while patients with TNBC who achieve a pCR appear to have a good DFS, patients with TNBC who have more than minimal residual disease at surgery have a much higher risk of early distant disease recurrence.16-18

Based on the fact that currently there are no approved targeted therapies for the neoadjuvant or palliative treatment of TNBC, identifying potential targets and developing effective targeted agents is greatly needed.

Heterogeneity of TNBC

It is well recognized that there are histologic and molecular differences in TNBC.19 From the histology point of view, the majority of TNBC corresponds to the invasive ductal carcinoma type (IDC). Other less commonly seen histologies include: Medullary carcinoma, metaplastic carcinoma, adenoid cystic carcinoma and apocrine carcinoma.20 The prognosis varies greatly among these different histology groups. Patients with metaplastic carcinoma have been identified to have higher relapse rates; a retrospective study by Bae and colleagues, demonstrated an inferior 3 year DFS in patients with lymph node metastasis who underwent adjuvant chemotherapy of 44.4% vs 72.5% when compared to TNBC-IDC (P=0.025).21 Medullary carcinomas on the other hand, are believed to have a better prognosis. This was demonstrated in an analysis of 13 International Breast Cancer Study Group (IBCSG) trials, where the 14 year DFS was 89% for patients with medullary carcinoma (ER negative and high grade tumors) vs 63% for patients with TNBC-IDC (HR 0.24, P=0.002).22 Adenoid cystic carcinomas have also been found to have a good prognosis with 5 year DFS typically above 90%.23

The triple negative clinical subtype comprises mainly the basal-like molecular subtype, but caution should be used when referring to TNBC in general as “basal like” tumors. As an example, 172 triple-negative tumors based on IHC staining were correlated with gene expression profiles that defined the basal subtype and only 71 % of TNBC were consistent with the basal subtype.24 At the molecular level, gene expression (GE) profiles from 587 TNBC cases by cluster analysis identified 6 TNBC types displaying unique GE and ontologies, including 2 basal-like (BL 1 and BL 2), an immunomodulatory (IM), a mesenchimal (M), a mesenchimal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.25 BL 1 and BL 2 subtypes have higher expression of cell cycle and DNA damage response genes, and representative cell lines that preferentially respond to platinum agents. The IM subtype is enriched for immune cell processes. M and MSL subtypes are enriched in GE for epithelial-mesenchymal transition and growth factor pathways, cell models of this the subtype responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/scr inhibitor). The LAR subtype includes patients with decreased relapse-free survival and is characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).25

Recent NACT trials with Cb in TNBC

There is a large body of literature indicating that patients with aggressive breast cancer subtypes who obtain a pCR to NACT have a better prognosis; this is especially true for the hormonal receptor negative (HR-) BC subtypes.17,18 Currently pCR is considered a surrogate endpoint for OS in patients receiving NACT for TNBC. The optimal chemotherapy regimen however remains to be determined. TNBC demonstrates sensitivity to DNA-damaging agents like platinum.10 Based on this finding a number of clinical trials have sought to determine if adding Cb to anthracycline-taxane based or simply taxane NACT would increase the pCR rates (Table 126-34).

In the phase II GeparSixto trial 315 patients with stage II to III TNBC were treated for 18 weeks with weekly paclitaxel (wP) 80 mg/m2 and non-pegylated-liposomal doxorubicin 20 mg/m2. Bevacizumab 15 mg/kg every 2 weeks (q 2w) was given concomitantly. All patients were randomized 1:1 to receive concurrently Cb AUC 2 but later on reduced to 1.5 secondary to toxicity. Primary outcome of the study was pCR rates.26 The addition of Cb increased pCR from 37% in the control group to 53% in patients that received Cb (P=0.005). Hematological side effects were more common in the Cb group and included grade ≥ 3 neutropenia 65% vs 27%, grade ≥ 3 anemia 15% vs <1% and grade ≥ 3 thrombocytopenia 14% vs 1%. Cb was more often associated with dose discontinuation, in 48% with Cb and 39% without Cb (P=0.031).26 The 3 year analysis shows that 85.8% of the patients treated with Cb were without evidence of disease vs 76.1% in the control group (HR 0.56, 95% CI 0.33-0.96, P=0.0350).27

In the randomized phase II trial conducted by the Cancer Leukemia Group (CALGB 40603), 443 patients with stage II to III TNBC received a backbone chemotherapy of wP 80 mg/m2 for 12 weeks, followed by doxorubicin plus cyclophosphamide q 2w (ddAC) for four cycles and were randomly assigned to concurrent Cb AUC 6 every 3 weeks (q 3 w) for four cycles and/or bevacizumab 10 mg/kg q 2 w for nine cycles.28 Employing one-sided P values, addition of either Cb (60% vs 44%; P=0.0018) or bevacizumab (59% vs 48%; P=0.0089) significantly increased pCR in the breast, whereas only Cb (54% vs 41%; P=0.0029) significantly raised pCR in the breast and axilla. Patients assigned to either Cb or bevacizumab were less likely to complete wP and ddAC without skipped doses, dose modification, or early discontinuation resulting from toxicity. Grade ≥ 3 neutropenia and thrombocytopenia were more common with Cb, as were hypertension, infection, thromboembolic events, bleeding, and postoperative complications with bevacizumab.28 The analysis of event free survival (EFS) and OS with a median follow-up duration of 39 months, showed that treatment with Cb or bevacizumab did not significantly affect either outcome. The addition of Cb was associated with an EFS hazard ratio (HR) of 0.84 (95% CI 0.58-1.22, P=0.36) and a survival HR of 1.15 (95% CI 0.74-1.79, P=0.53). Outcomes were similar with the addition of bevacizumab.29

The ISPY-2, randomized 60 women whose tumors had a genomic signature consistent with TNBC to receive wP 80 mg/m2 for 12 weeks, followed by ddAC for four cycles, with or without an experimental regimen consisting of Cb AUC 6 q 3 w for four cycles and the oral poly-ADP ribose polymerase (PARP) inhibitor, veliparib (50 mg twice daily by mouth).30 The study demonstrated a pCR of 51% in the veliparib-Cb containing arm [95% probability interval (PI) 36-66%] compared to 26% in the control arm (95% PI 9-43%). Given the design of the study, it is difficult to determine how much the addition of the PARP-inhibitor added to the effect of Cb. Early detection of therapy response or resistance in the neoadjuvant setting may help to optimize the chemotherapy strategy. In the phase II Adjuvant Dynamic Marker-Adjusted Personalized Therapy (ADAPT) triple negative trial, 336 patients with centrally confirmed TNBC were randomized to receive nab-paclitaxel at 125 mg/m2 either with Cb AUC 2 or Gemcitabine 1000 mg/m2.31 The study reported pCR of 45.9% vs 28.7 %, favoring the Cb containing arm. Early response was predictive of pCR regardless of the treatment arm. The observed efficacy in this study seems comparable to longer and less tolerable anthracycline-taxane containing regimens. Patients that did not achieve a pCR in the study were offered standard post-operative chemotherapy with epirubicin and cyclophosphamide for 4 cycles. It is unknown if outcome is affected by the type of chemotherapy administered in order to obtain a pCR. Anthracyclines are associated with long-term worrisome side effects, especially cardiotoxicity and leukemia.32 There have been studies looking at omitting these agents in the adjuvant treatment of TNBC, but so far it has been demonstrated that 6 cycles of docetaxel in combination with cyclophosphamide is associated with a higher breast cancer recurrence, when compared to standard anthracycline-taxane based regimens.33 This raises the question if results could be improved by combining docetaxel with Cb instead. A prospective multisite registry study evaluated Docetaxel in combination with Cb and included 76 patients with ≥ T1c to Stage III TNBC. Patients received 4-6 cycles of docetaxel 75 mg/m2 in combination with Cb AUC 6 given q 3 w. This regimen produced pCR in 66% of the patients. With a median follow up of 2.3 years the cohort of patients that achieve a pCR demonstrated a 95% recurrence free survival.34

Can we select patients that benefit from the addition of Cb to NACT?

Gene defects in the homologous recombination (HR) pathway are of potential therapeutic relevance in a variety of cancers. Clinical studies have demonstrated that BRCA1/2-deficient tumors are sensitive to both platinum salts and PARP-inhibitors.35,36 The three DNA-based homologous recombination deficiency (HRD) scores: HRD-loss of heterozygosity score (LOH), HRD-telomeric allelic imbalance score (TAI), and HRD-large-scale state transition score (LST) are highly correlated with defects in BRCA1/2, and are associated with response to platinum therapy in triple negative breast and ovarian cancer.37-40

Analysis of triple negative tumors in the GeparSixto clinical trial found HR deficiency in 136 (70.5%) tumors; 82 (60%) of them showed high HRD score (LOH score + TAI score + LST score ≥ 42) without BRCA mutation. The study utilized the HRD assay developed by Myriad Genetics Inc. (Salt lake City, UT, https://www.myriad.com). HR deficiency was associated with a higher rate of pCR 55.9% vs 29.8% (P=0.001). Adding carboplatin (Cb) to the paclitaxel, non-pegylated-liposomal doxorubicin and bevacizumab combination increased the pCR rate from 45.2% to 64.9% in HR deficient tumors (P=0.025). This effect was also seen in patients with somatic BRCA mutations, where the pCR rate was increased from 38.1% to 69.7% with the addition of Cb (P=0.022). The pCR rate in the HR non-deficient patients was 20% without Cb and 40.7% with Cb, but did not reach statistical significance (P=0.146).41

Pooled analysis of six phase II clinical trials (including GeparSixto), in which patients with TNBC received a platinum agent, demonstrated that patients with high HRD score were significantly more likely to achieve a pCR than those with HR-nondeficient tumors: 53% vs 18% (adjusted odds ratio = 4.64; P<0.0001), regardless of BRCA1/2 mutation status.42 To further support the fact that the presence of a BRCA-1 mutation confers high sensitivity to platinum agents, Byrski and colleagues treated 107 patients with BRCA-1 associated breast cancer with single agent cisplatin 75 mg/m2 every 3 weeks for 4 cycles. The study demonstrated a very significant pCR rate of 61%, considering anthracyclines and taxanes were not given.43

Masuda and colleagues evaluated clinical outcomes in 130 patients based on subtypes of TNBC.16 They found that patients with the basal-like 1 subtype had the highest pCR rate (52%). In contrast, those with the LAR subtype had one of the lowest pCR rates (10%). However, despite their low pCR rate, OS was better in patients with the LAR subtype.16 These findings indicate that perhaps the LAR molecular subtype of TNBC may not benefit from more intense NACT protocols that add Cb.

Although specific tests are not approved or commercially available at the moment, it is possible that in the future, the NACT agents could be tailored according to the molecular subtype of TNBC. Adding Cb could be more beneficial in subtypes other than the LAR. It is also possible that addition of Cb could at some point be selected based on high HRD scores or the presence of a somatic or germline mutation for BRCA.

Prognostic significance of pCR in TNBC

Evidence from accumulated neoadjuvant studies reveals that pCR provides a surrogate marker that is predictive of long-term clinical response and survival in TNBC patients.14,15 Despite its widespread use, there is still no uniform definition of pCR. Three definitions have been traditionally used by different investigators: i) ypT0 ypN0: absence of invasive cancer and in situ cancer in the breast and axillary nodes; ii) ypT0/is ypN0: absence of invasive cancer in the breast and axillary nodes, irrespective of carcinoma in situ; iii) ypT0/is: absence of invasive cancer in the breast, irrespective of ductal carcinoma in situ or nodal involvement.

Two large meta-analyses have looked at the long-term outcomes of patients achieving pCR after NACT. Both studies have demonstrated a major benefit in the long-term outcome from achieving a pCR in patients with aggressive BC subtypes (triplenegative; HR-/HER2-positive and high-grade HR+/HER2-negative).17,18

In the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie Breast (AGO-B) study groups, seven prospective clinical trials with a total of 6377 patients receiving neoadjuvant anthracycline-taxane-based chemotherapy were analyzed during a median follow up of 46.3 months. Prognostic impact of pCR on DFS was demonstrated in 4193 patients according to the breast cancer intrinsic subtype. The eradication of tumor from both breast and lymph nodes (ypT0/is ypN0 and ypT0 ypN0) compared to the absence of tumor in breast only (ypT0/is) revealed a stronger association with improved EFS and OS. TNBC represented 15% of the study group and demonstrated a pCR (ypT0 ypN0) of 44%. Progression free survival in this subgroup of patients with pCR was over 90% at 5 years (P<0.001).17

The US Food and Drug Administration established an international working group known as Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). The study included 12 international neoadjuvant trials with 11,955 patients in the pooled responder analysis. Patients who achieved a pCR had longer EFS and OS than did patients with residual invasive cancer. Eradication of tumor from both the breast and axillary lymph nodes (ypT0pN0 and ypT0/is ypN0) was better associated with improved EFS and OS than was eradication of invasive tumor from the breast alone (ypT0/is). The association between pCR and long-term outcomes was strongest in patients with TNBC (EFS: HR 0.24, 95% CI 0. 18–0.33; OS: 0.16, 0.11-0.25).18 However, the trial-level association between pCR and long-term outcome by tumor subtype recorded no correlation between improvement in frequency of pCR and the treatment’s effect on EFS or OS. It is possible that different biological subtypes of BC require a different end point definition regarding pCR to indicate a survival benefit and the inclusion of heterogeneous populations may have obscured the association. It has also been indicated that large increases in pCR between the control group and investigation arm will be needed in NACT studies to demonstrate a statistically significant change in survival.44,45 This maybe the reason behind the fact that improvement in pCR by 20% in the case of the Neo-ALLTO trial, narrowly missed statistical significance in the ALLTO trial (HR 0.84, 97.5 % CI 0.70-1.02).46,47

Selected ongoing Cb NACT studies in TNBC

There are several studies evaluating various schedules and combinations of Cb in the NACT of TNBC (Table 2). The phase II NeoStop clinical trial determines the need for anthracyclines in the NACT setting by randomizing patients to a non-anthracycline containing arm of Docetaxel and Cb in standard dose and frequency given for six cycles vs. weekly paclitaxel in combination with Cb followed by ddAC. The study’s primary endpoint is pCR rates (NCT02413320). The phase III PEARLY clinical trial is randomizing patients to receive a taxane-anthracycline chemotherapy plus or minus Cb, in either the neoadjuvant or adjuvant setting. The primary outcome of the study is five-year EFS, secondary outcomes include pCR rates and long-term effects of Cb (NCT02441933).

The 50-gene qPCR assay (PAM50) can identify the intrinsic biological BC subtypes using RNA isolated from more readily available formalin-fixed, paraffin-embedded (FFPE) tissue. These subtypes can also be assessed using a multiplexed gene-expression profiling technology (NanoString Technologies; Seattle, WA, USA). The PAM50 gene set provides a risk of relapse score not only in ER-positive, node negative patients (similarly to the Oncotype Dx Recurrence Score) but also in the ER negative disease. Additionally, the PAM50 assay is highly predictive of neoadjuvant response when considering all BC subtypes.48 This test is being used to identify predictors of response to NACT with docetaxel and Cb (NCT01560663). The GeparOla multicenter, prospective, randomized, open-label phase II clinical trial, is testing the effect of adding olaparib to weekly paclitaxel and Cb followed by epirubin and cyclophosphamide (NCT02789332). Patients will have centrally confirmed tumor high HRD score and known germline BRCA and/or tumor BRCA mutation. The study is looking at pCR rates and assessing the effect of olaparib in this population of patients. Immune checkpoint inhibitors have demonstrated activity as single agents in the treatment of advanced TNBC.49 The effect is potentiated by the addition of nab-paclitaxel.50 To explore this effect in NACT of TNBC, the randomized clinical trial NeoTRIPaPDLlaims to evaluate the addition of ate-zolizumab to Cb and nab-paclitaxel in patients with locally advanced TNBC (NCT02620280).

Conclusions

The long-term survival effect of the addition of Cb to standard NACT regimens remains unclear. The 3 year follow up of the GeparSixto clinical trial demonstrated an EFS advantage favoring the Cb containing arm, while the CALGB40603 39 month median follow up report did not show a statistical difference in EFS or OS with the addition of Cb. It is important to understand that neither one of these two studies were powered to demonstrate EFS differences. Since there are no targeted therapies currently approved for the NACT of TNBC, we need to continue to rely on chemotherapies with the goal of increasing pCR rates. Based on the fact that pCR confers a good prognosis, it seems reasonable to continue to seek this outcome. The improvement in pCR seen in these trials however, comes at the cost of increased toxicity, dose reductions and omissions, which were needed in up to 40-50% of the patients. Ongoing randomized phase III clinical trials will hopefully provide more information on the survival effect, as well as on long-term toxicity with the addition of Cb to adjuvant chemotherapy (NCT02488967, NCT02441933).

Based on the fact that TNBC constitutes a heterogeneous group of disease, it is important to point out that future studies will need to individualize therapies according to the different subgroups of TNBC. Current studies have started to evaluate the addition of Cb to NACT based on high HRD scores. Other studies test its addition to patients with molecular profiling consistent with the basal subtype. Once the patients that are likely to benefit from the addition of Cb to NACT are identified, this may result in improved response to treatment demonstrated by higher rates of pCR. Most importantly, patients that are not likely to benefit will be spared from the additional toxicity of Cb.

Until more information is available, the addition of Cb to standard NACT for TNBC should be individualized. Currently it is acceptable to add it in the following cases: BRCA-associated BC, patients with inflammatory BC or for those who present with locally advanced disease. Patients should be healthy enough and clinically fit to tolerate the increased toxic effect of adding Cb to standard NACT. At this time, treating TNBC patients with NACT, which does not incorporates anthracyclines, remains investigational. If possible, patients should be enrolled in ongoing Cb NACT studies looking to answer the questions raised above.

References

1. 

KF Trivers, MJ Lund, PL Porter. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071.

2. 

WD Foulkes, IE Smith, JS Reis-Filho. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.

3. 

NU Lin, E Claus, J Sohl, AR Razzak. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 2008;113:2638-45.

4. 

LF Hernandez-Aya, M Chavez-Macgregor, X Lei. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011;29:2628-34.

5. 

R Dent, M Trudeau, KI Pritchard. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.

6. 

AM Gonzalez-Angulo, KM Timms, S Liu. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17: 1082-9.

7. 

AR Hartman, RR Kaldate, LM Sailer. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012;118:2787-95.

8. 

ME Hammond, DF Hayes, M Dowsett. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784.

9. 

SJ Isakoff. Triple-negative breast cancer: role of specific chemotherapy. Cancer J 2010;16:53-61.

10. 

G von Minckwitz, M. Martin Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 2012;23: vi35-9.

11. 

KD Amos, B Adamo, CK Anders. Triple-negative breast cancer: An update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978.

12. 

F Kassam, K Enright, R Dent. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009;9:29-33.

13. 

LA Carey, EC Dees, L Sawyer. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.

14. 

C Liedtke, C Mazouni, KR Hess. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.

15. 

JS Mieog, JA van der Hage, CJ van de Velde. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;2:CD005002.

16. 

R Dent, WM Hanna, M Trudeau. Time to disease recurrence in basal-type breast cancers: effects of tumour size and lymph node status. Cancer 2009;115:4917-23.

17. 

G von Minckwitz, M Untch, JU Blohmer. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.

18. 

P Cortazar, L Zhang, M Untch. The CTNeoBC pooled analysis. Lancet 2014;384:164-72.

19. 

A Constantinidou, RL Jones, JS Reis-Filho. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther 2010;10:1197-213.

20. 

Y Ishikawa, J Horiguchi, H Toya. Triple-negative breast cancer: Histological subtypes and immunohistochemical and clinicopathological features. Cancer Scic 2011;102:656-62.

21. 

SY Bae, SK Lee, MY Koo. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 2011;126:471-8.

22. 

J Huober, S Gelber, A Goldhirsch. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012;23:2843-51.

23. 

N Kulkarni, CM Pezzi, JM Greif. Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base. Ann Surg Oncol 2013;20:2236-41.

24. 

F Bertucci, P Finetti, N Cervera. How basal are triple-negative breast cancers? Int J Cancer 2008;123:236.

25. 

BD Lehmann, JA Bauer, X Chen. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750.

26. 

G von Minckwitz, A Schneeweiss, S Loibl. Neoadjuvant arboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014;15:747.

27. 

G von Minckwitz, S Loibl, A Schneeweiss. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). SABCS. 2015; abstr S2-04.

28. 

WM Sikov, DA Berry, CM Perou. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week followed by dose-dense doxorubicin and on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin 2015;33:13.

29. 

WM Sikov, DA Berry, CM Perou. Event-free and overall survival following neoadjuvant weekly paclitaxel and dosedense AC +/-carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). SABC. 2015; abstr S2-05.

30. 

HS Rugo, OI Olopade, A DeMichele. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med 2016;375:23-34.

31. 

O Gluz, U Nitz, C Liedtke. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. SABCS. 2015; abstr S6-07

32. 

CG Valentini, L Fianchi, MT Voso. Incidence of acute myeloid leukemia after breast cancer. Mediterr J Hematol Infect Dis 2011;3:e2011069.

33. 

JL Blum, PJ Flynn, G Yothers. Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. ASCO 2016; Abstr 1000.

34. 

P Sharma, BF Kimler, C Ward. Prognoses of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy. J Clin Oncol 2016;34: abstr 1015.

35. 

GE Konecny, RS Kristeleit. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73.

36. 

ML Telli, K Timms, JE Reid. Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer. ASCO 2015.

37. 

V Abkevich, KM Timms, BT Hennessy. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776-82.

38. 

NJ Birkbak, ZC Wang, J-Y Kim, AC Eklund. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA damaging agents. Cancer Discov 2012;2:366-75.

39. 

T Popova, E Manie, G Rieunier. Ploidy and large-scale genomic instability consistently identify basallike breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454-62.

40. 

KM Timms, V Abkevich, E Hughes. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014;16:475.

41. 

G von Minckwitz, K Timms, M Untch. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. J Clin Oncol 2015;33: abstr 1004.

42. 

ML Telli, KM Timms, J Reid. Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer. SABCS. 2015; abstr P3-07-12.

43. 

T Byrski, T Huzarski, R Dent. Pathologic complete response to cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014;147:401.

44. 

H Masuda, KA Baggerly, Y Wang. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-40.

45. 

A Pennisi, T Kieber-Emmons, I Makhoul. Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. Breast Cancer (Auckl) 2016;10:103-6.

46. 

J Baselga, I Bradbury, H Eidtmann. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.

47. 

MJ Piccart-Gebhart, AP Holmes, J Baselga. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with Lapatinib alone (L), trastuzumab alone (T), their sequence (T then L), or their combinations (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) [abstract] J Clin Oncol 2014;32:LBA4.

48. 

MC Liu, BN Pitcher, ER Mardis. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) npj. Breast Cancer 2016;2:15023.

49. 

R Nanda, LQ Chow, EC Dees. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol 2016 [Epub ahead of print].

50. 

S Adams, J Diamond, E Hamilton. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. J Clin Oncol 2016;34: abstr 1009.

Table 1.

Selected Cb NACT trials in TNBC.

Study
[reference]
Study
design
Chemotherapy
regimen
N PCR
definition
used
PCR
(%)
Control
PCR
(%)
Platinum
GeparSixto26 Randomized phase II wP + nPLD 20 mg/m2 qw + B 15 mg/kg q 3w ± Cb AUC 1.5-2 qw x 18 w 315 ypT0 ypN0 37 53
CALGB 4060328 Randomized phase II wP x 12 ± Cb AUC 6 q 3w x 4 → ddAC x 4 ± B 10 mg/kg q 2w x 9 433 ypT0/is ypN0 41 54
ISPY-230 Randomized phase II wP x 12 ± Cb AUC 6 q 3w x 4 + veliparib → ddAC x 4 60 ypT0/is ypN0 26 51
ADAPT31 Randomized phase II weekly nap-paclitaxel 125 mg/m2 + Cb AUC 2 or gemcitabine 1,000 mg/m2 on day 1 and 8 q 3w x 4 336 ypT0/is ypN0 28.7 45.9
Sharma et al.34 Observational Cb AUC 6 + Docetaxel 75 mg/m2 3w x 4-6 cycles 76 ypT0/is ypN0 na 66

[i] Abbreviations: AC, doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2; ddAC, dose dense AC; Cb, carboplatin; AUC, area under the curve; B, Bevacizumab; wP, weekly paclitaxel 80 mg/m2; nPLD, non-pegylated-liposomal doxorubicin; pCR, complete pathologic response; na, not available; qw, every week; q 2w, every 2 weeks; q 3w, every 3 weeks; ypT0 ypN0, absence of invasive cancer and in situ cancer in the breast and axillary nodes; ypT0/is ypN0, absence of invasive cancer in the breast and axillary nodes, irrespective of carcinoma in situ.

Table 2.

Selected active NACT evaluating the addition of carboplatin in TNBC.

NCI Identifier (Acronym) Phase Study design Chemotherapy regimen
NCT02413320
NeoSTOP
II Randomized, open-label wP x 12 + Cb AUC 6 q 3w x 4 → ddAC x 4 vs Docetaxel 75 mg/m2 + Cb AUC 6 q 3w x 6
NCT02441933
PEARLY
III Randomized, open-label AC x 4 q 3 w → taxane (Docetaxel 75 mg/m2 q 3w x 4 or wP x 12) ± Cb AUC 5 q 3w x 4
NCT02789332
GeparOla
II Randomized, open-label wP + olaparib 100 mg bid x 12 w or Cb AUC 2 q w x 12 → EC q 2-3w x 4
NCT01560663 II Observational, case control Docetaxel 75 mg/m2 + Cb AUC 6 q 3w x 6
NCT02620280
NeoTRIPaPDLl
II Randomized, open-label Cb AUC 2 + nab-paclitaxel 125 mg/m2 on day 1 and 8 q 3 w x 8 ± atezolizumab 1200 mg i.v. on day 1 q 3 w x 8

[i] Abbreviations: AC, doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2; ddAC, dose dense AC; Cb, carboplatin; AUC, area under the curve; wP, paclitaxel 80 mg/m2 weekly; i.v, intravenous; bid, twice a day; qw, every week; q 2w, every 2 weeks; q 3w, every 3 weeks.

Abstract views:
1012

Views:
PDF
436
HTML
156

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Aurelio Bartolome Castrellon, Ihor Pidhorecky, Vicente Valero, Luis Estuardo Raez

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185